293 related articles for article (PubMed ID: 32752061)
21. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status.
Gorantla S; Singhvi G; Rapalli VK; Waghule T; Dubey SK; Saha RN
Ther Deliv; 2020 Apr; 11(4):269-284. PubMed ID: 32434463
[TBL] [Abstract][Full Text] [Related]
22. Advances in local drug delivery technologies for improved rheumatoid arthritis therapy.
An X; Yang J; Cui X; Zhao J; Jiang C; Tang M; Dong Y; Lin L; Li H; Wang F
Adv Drug Deliv Rev; 2024 Jun; 209():115325. PubMed ID: 38670229
[TBL] [Abstract][Full Text] [Related]
23. Dietary polyphenols for management of rheumatoid arthritis: Pharmacotherapy and novel delivery systems.
Maity S; Wairkar S
Phytother Res; 2022 Jun; 36(6):2324-2341. PubMed ID: 35318759
[TBL] [Abstract][Full Text] [Related]
24. Hyaluronic acid-coated solid lipid nanoparticles enhance antirheumatic activity and reduce toxicity of methotrexate.
Mirchandani Y; Patravale VB; Brijesh S
Nanomedicine (Lond); 2022 Jul; 17(16):1099-1114. PubMed ID: 36178114
[TBL] [Abstract][Full Text] [Related]
25. Optimization and Development of Methotrexate- and Resveratrol-Loaded Nanoemulsion Formulation Using Box-Behnken Design for Rheumatoid Arthritis.
Poonia N; Lather V; Kaur B; Kirthanashri SV; Pandita D
Assay Drug Dev Technol; 2020; 18(8):356-368. PubMed ID: 33052698
[No Abstract] [Full Text] [Related]
26. Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-κB and FOXO1.
Garg NK; Tyagi RK; Singh B; Sharma G; Nirbhavane P; Kushwah V; Jain S; Katare OP
Int J Pharm; 2016 Feb; 499(1-2):301-320. PubMed ID: 26768725
[TBL] [Abstract][Full Text] [Related]
27. Nanomedicine for the Treatment of Rheumatoid Arthritis.
Jeong M; Park JH
Mol Pharm; 2021 Feb; 18(2):539-549. PubMed ID: 32502346
[TBL] [Abstract][Full Text] [Related]
28. Enhanced Therapeutic Effect of RGD-Modified Polymeric Micelles Loaded With Low-Dose Methotrexate and Nimesulide on Rheumatoid Arthritis.
Wang Y; Liu Z; Li T; Chen L; Lyu J; Li C; Lin Y; Hao N; Zhou M; Zhong Z
Theranostics; 2019; 9(3):708-720. PubMed ID: 30809303
[TBL] [Abstract][Full Text] [Related]
29. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
Saito S; Takeuchi T
J Clin Exp Hematop; 2019; 59(4):145-155. PubMed ID: 31866617
[TBL] [Abstract][Full Text] [Related]
30. New biologics for rheumatoid arthritis.
Choy E
J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
[TBL] [Abstract][Full Text] [Related]
31. Biomimetic hydroxyapatite as potential polymeric nanocarrier for the treatment of rheumatoid arthritis.
Ain Q; Zeeshan M; Khan S; Ali H
J Biomed Mater Res A; 2019 Dec; 107(12):2595-2600. PubMed ID: 31373751
[TBL] [Abstract][Full Text] [Related]
32. Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine.
Halik PK; Koźmiński P; Gniazdowska E
Mol Pharm; 2021 Jan; 18(1):33-43. PubMed ID: 33251808
[TBL] [Abstract][Full Text] [Related]
33. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
Rubinstein I; Weinberg GL
Nanomedicine; 2012 Sep; 8 Suppl 1():S77-82. PubMed ID: 22640912
[TBL] [Abstract][Full Text] [Related]
34. Nanotherapeutics relieve rheumatoid arthritis.
Yang M; Feng X; Ding J; Chang F; Chen X
J Control Release; 2017 Apr; 252():108-124. PubMed ID: 28257989
[TBL] [Abstract][Full Text] [Related]
35. Nanomedical approaches in the realm of rheumatoid arthritis.
Radu AF; Bungau SG
Ageing Res Rev; 2023 Jun; 87():101927. PubMed ID: 37031724
[TBL] [Abstract][Full Text] [Related]
36. Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis.
Rahman M; Beg S; Sharma G; Saini S; Rub RA; Aneja P; Anwar F; Alam MA; Kumar V
Recent Pat Antiinfect Drug Discov; 2016; 11(1):3-15. PubMed ID: 27193030
[TBL] [Abstract][Full Text] [Related]
37. Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery.
Rahman M; Beg S; Verma A; Al Abbasi FA; Anwar F; Saini S; Akhter S; Kumar V
J Pharm Pharmacol; 2017 Jan; 69(1):1-14. PubMed ID: 27774648
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronate-functionalized hydroxyapatite nanoparticles laden with methotrexate and teriflunomide for the treatment of rheumatoid arthritis.
Pandey S; Rai N; Mahtab A; Mittal D; Ahmad FJ; Sandal N; Neupane YR; Verma AK; Talegaonkar S
Int J Biol Macromol; 2021 Feb; 171():502-513. PubMed ID: 33422513
[TBL] [Abstract][Full Text] [Related]
39. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy.
Han Y; Huang S
J Control Release; 2023 Apr; 356():142-161. PubMed ID: 36863691
[TBL] [Abstract][Full Text] [Related]
40. Nanostructures for protein drug delivery.
Pachioni-Vasconcelos Jde A; Lopes AM; Apolinário AC; Valenzuela-Oses JK; Costa JS; Nascimento Lde O; Pessoa A; Barbosa LR; Rangel-Yagui Cde O
Biomater Sci; 2016 Feb; 4(2):205-18. PubMed ID: 26580477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
